Cargando…
Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia
BACKGROUND/AIMS: We evaluated the feasibility and long-term efficacy of the combination of cytarabine, idarubicin, and all-trans retinoic acid (ATRA) for treating patients with newly diagnosed acute promyelocytic leukemia (APL). METHODS: We included 87 patients with newly diagnosed acute myeloid leu...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association of Internal Medicine
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271710/ https://www.ncbi.nlm.nih.gov/pubmed/35811370 http://dx.doi.org/10.3904/kjim.2021.468 |
_version_ | 1784744728790564864 |
---|---|
author | Park, Young Hoon Kim, Dae-Young Mun, Yeung-Chul Cho, Eun Kyung Lee, Jae Hoon Jo, Deog-Yeon Kim, Inho Yoon, Sung-Soo Park, Seon Yang Kim, Byoungkook Bang, Soo-Mee Kim, Hawk Min, Young Joo Park, Jae Hoo Seo, Jong Jin Moon, Hyung Nam Lee, Moon Hee Kim, Chul Soo Lee, Won Sik Chong, So Young Oh, Doyeun Zang, Dae Young Lee, Kyung Hee Hyun, Myung Soo Kim, Heung Sik Kim, Sung-Hyun Kwon, Hyukchan Kim, Hyo Jin Park, Kyung Tae Bae, Sung Hwa Ryoo, Hun Mo Choi, Jung Hye Ahn, Myung-Ju Yoon, Hwi-Joong Nam, Sung-Hyun Kim, Bong-Seog Seong, Chu-Myong |
author_facet | Park, Young Hoon Kim, Dae-Young Mun, Yeung-Chul Cho, Eun Kyung Lee, Jae Hoon Jo, Deog-Yeon Kim, Inho Yoon, Sung-Soo Park, Seon Yang Kim, Byoungkook Bang, Soo-Mee Kim, Hawk Min, Young Joo Park, Jae Hoo Seo, Jong Jin Moon, Hyung Nam Lee, Moon Hee Kim, Chul Soo Lee, Won Sik Chong, So Young Oh, Doyeun Zang, Dae Young Lee, Kyung Hee Hyun, Myung Soo Kim, Heung Sik Kim, Sung-Hyun Kwon, Hyukchan Kim, Hyo Jin Park, Kyung Tae Bae, Sung Hwa Ryoo, Hun Mo Choi, Jung Hye Ahn, Myung-Ju Yoon, Hwi-Joong Nam, Sung-Hyun Kim, Bong-Seog Seong, Chu-Myong |
author_sort | Park, Young Hoon |
collection | PubMed |
description | BACKGROUND/AIMS: We evaluated the feasibility and long-term efficacy of the combination of cytarabine, idarubicin, and all-trans retinoic acid (ATRA) for treating patients with newly diagnosed acute promyelocytic leukemia (APL). METHODS: We included 87 patients with newly diagnosed acute myeloid leukemia and a t(15;17) or promyelocytic leukemia/retinoic acid receptor alpha (PML-RARα) mutation. Patients received 12 mg/m(2)/day idarubicin intravenously for 3 days and 100 mg/m(2)/day cytarabine for 7 days, plus 45 mg/m(2)/day ATRA. Clinical outcomes included complete remission (CR), relapse-free survival (RFS), overall survival (OS), and the secondary malignancy incidence during a 20-year follow-up. RESULTS: The CR, 10-year RFS, and 10-year OS rates were 89.7%, 94.1%, and 73.8%, respectively, for all patients. The 10-year OS rate was 100% for patients that achieved CR. Subjects were classified according to the white blood cell (WBC) count in peripheral blood at diagnosis (low-risk, WBC < 10,000/mm(3); high-risk, WBC ≥ 10,000/mm(3)). The low-risk group had significantly higher RFS and OS rates than the high-risk group, but the outcomes were not superior to the current standard treatment (arsenic trioxide plus ATRA). Toxicities were similar to those observed with anthracycline plus ATRA, and higher than those observed with arsenic trioxide plus ATRA. The secondary malignancy incidence after APL treatment was 2.7%, among the 75 patients that achieved CR, and 5.0% among the 40 patients that survived more than 5 years after the APL diagnosis. CONCLUSIONS: Adding cytarabine to anthracycline plus ATRA was not inferior to anthracycline plus ATRA alone, but it was not comparable to arsenic trioxide plus ATRA. The probability of secondary malignancy was low. |
format | Online Article Text |
id | pubmed-9271710 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Korean Association of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-92717102022-07-13 Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia Park, Young Hoon Kim, Dae-Young Mun, Yeung-Chul Cho, Eun Kyung Lee, Jae Hoon Jo, Deog-Yeon Kim, Inho Yoon, Sung-Soo Park, Seon Yang Kim, Byoungkook Bang, Soo-Mee Kim, Hawk Min, Young Joo Park, Jae Hoo Seo, Jong Jin Moon, Hyung Nam Lee, Moon Hee Kim, Chul Soo Lee, Won Sik Chong, So Young Oh, Doyeun Zang, Dae Young Lee, Kyung Hee Hyun, Myung Soo Kim, Heung Sik Kim, Sung-Hyun Kwon, Hyukchan Kim, Hyo Jin Park, Kyung Tae Bae, Sung Hwa Ryoo, Hun Mo Choi, Jung Hye Ahn, Myung-Ju Yoon, Hwi-Joong Nam, Sung-Hyun Kim, Bong-Seog Seong, Chu-Myong Korean J Intern Med Original Article BACKGROUND/AIMS: We evaluated the feasibility and long-term efficacy of the combination of cytarabine, idarubicin, and all-trans retinoic acid (ATRA) for treating patients with newly diagnosed acute promyelocytic leukemia (APL). METHODS: We included 87 patients with newly diagnosed acute myeloid leukemia and a t(15;17) or promyelocytic leukemia/retinoic acid receptor alpha (PML-RARα) mutation. Patients received 12 mg/m(2)/day idarubicin intravenously for 3 days and 100 mg/m(2)/day cytarabine for 7 days, plus 45 mg/m(2)/day ATRA. Clinical outcomes included complete remission (CR), relapse-free survival (RFS), overall survival (OS), and the secondary malignancy incidence during a 20-year follow-up. RESULTS: The CR, 10-year RFS, and 10-year OS rates were 89.7%, 94.1%, and 73.8%, respectively, for all patients. The 10-year OS rate was 100% for patients that achieved CR. Subjects were classified according to the white blood cell (WBC) count in peripheral blood at diagnosis (low-risk, WBC < 10,000/mm(3); high-risk, WBC ≥ 10,000/mm(3)). The low-risk group had significantly higher RFS and OS rates than the high-risk group, but the outcomes were not superior to the current standard treatment (arsenic trioxide plus ATRA). Toxicities were similar to those observed with anthracycline plus ATRA, and higher than those observed with arsenic trioxide plus ATRA. The secondary malignancy incidence after APL treatment was 2.7%, among the 75 patients that achieved CR, and 5.0% among the 40 patients that survived more than 5 years after the APL diagnosis. CONCLUSIONS: Adding cytarabine to anthracycline plus ATRA was not inferior to anthracycline plus ATRA alone, but it was not comparable to arsenic trioxide plus ATRA. The probability of secondary malignancy was low. Korean Association of Internal Medicine 2022-07 2022-06-28 /pmc/articles/PMC9271710/ /pubmed/35811370 http://dx.doi.org/10.3904/kjim.2021.468 Text en Copyright © 2022 The Korean Association of Internal Medicine https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Park, Young Hoon Kim, Dae-Young Mun, Yeung-Chul Cho, Eun Kyung Lee, Jae Hoon Jo, Deog-Yeon Kim, Inho Yoon, Sung-Soo Park, Seon Yang Kim, Byoungkook Bang, Soo-Mee Kim, Hawk Min, Young Joo Park, Jae Hoo Seo, Jong Jin Moon, Hyung Nam Lee, Moon Hee Kim, Chul Soo Lee, Won Sik Chong, So Young Oh, Doyeun Zang, Dae Young Lee, Kyung Hee Hyun, Myung Soo Kim, Heung Sik Kim, Sung-Hyun Kwon, Hyukchan Kim, Hyo Jin Park, Kyung Tae Bae, Sung Hwa Ryoo, Hun Mo Choi, Jung Hye Ahn, Myung-Ju Yoon, Hwi-Joong Nam, Sung-Hyun Kim, Bong-Seog Seong, Chu-Myong Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia |
title | Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia |
title_full | Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia |
title_fullStr | Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia |
title_full_unstemmed | Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia |
title_short | Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia |
title_sort | long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271710/ https://www.ncbi.nlm.nih.gov/pubmed/35811370 http://dx.doi.org/10.3904/kjim.2021.468 |
work_keys_str_mv | AT parkyounghoon longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT kimdaeyoung longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT munyeungchul longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT choeunkyung longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT leejaehoon longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT jodeogyeon longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT kiminho longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT yoonsungsoo longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT parkseonyang longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT kimbyoungkook longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT bangsoomee longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT kimhawk longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT minyoungjoo longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT parkjaehoo longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT seojongjin longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT moonhyungnam longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT leemoonhee longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT kimchulsoo longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT leewonsik longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT chongsoyoung longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT ohdoyeun longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT zangdaeyoung longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT leekyunghee longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT hyunmyungsoo longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT kimheungsik longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT kimsunghyun longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT kwonhyukchan longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT kimhyojin longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT parkkyungtae longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT baesunghwa longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT ryoohunmo longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT choijunghye longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT ahnmyungju longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT yoonhwijoong longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT namsunghyun longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT kimbongseog longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia AT seongchumyong longtermfollowupresultsofcytarabinecontainingchemotherapyforacutepromyelocyticleukemia |